Physician profile
Mathew Tilson
NPI 1467763813
$20,762.12
in general payments reported to CMS, 2019-2025
68 companies · $3,808 in 2025
The $3,808 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,780 · 2022: $3,125 · 2023: $7,471 · 2024: $3,578 · 2025: $3,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,830 · Travel and Lodging: $1,128 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,748.87 |
| Consulting Fee | $1,830.00 |
| Travel and Lodging | $1,128.14 |
| Education | $150.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,594.38 | 2021-2025 | Epclusa |
| Abbvie INC. | $3,626.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,392.91 | 2021-2025 | Fasenra, Airsupra, Farxiga |
| Pfizer INC. | $989.81 | 2021-2025 | |
| Novo Nordisk INC | $839.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $803.20 | 2021-2024 | Gattex, Trintellix, Eohilia |
| Lilly USA, LLC | $779.81 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $771.39 | 2021-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $528.24 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.36 | 2021-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $482.36 | 2021-2025 | Fanapt |
| Daiichi Sankyo INC. | $348.70 | 2021-2023 | Injectafer |
| Orexo US, INC. | $332.74 | 2022-2025 | Zubsolv |
| Glaxosmithkline, LLC. | $313.27 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $267.99 | 2021-2025 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Tilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.